Jennifer Tram
Nurse Practitioner · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · El Camino Health Medical Network LLC · The Board of Trustees of the University of Illinois
Looking this up.
Hospitals listed: University of Illinois Hospital and Clinics. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Jennifer Tram’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- University of Illinois Hospital and ClinicsChicago, ILAcute Care Hospital · Government - State · Has an emergency department · Birthing-friendlyPart of UI HealthPatients rate it 3 of 5 · 65% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.379, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.273, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.151, Oct 2024 – Sep 2025
See every measure and the patient survey for University of Illinois Hospital and Clinics
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.379 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.273 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.151 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0.08 to 1.99) · 1,194 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.13 (0.85 to 1.42) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 179.54 (131 to 228.08) · 97 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.6 · 26 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.1 · 150 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.3 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 200 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 1,414 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.01 to 0.44) · 4,308 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.42) · 4,585 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.89 (2.78 to 7) · 1,289 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.37 (0 to 2.93) · 462 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3.07 (1.72 to 4.43) · 1,194 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.02 (6.54 to 17.5) · 604 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.43 (1.24 to 7.63) · 579 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.54 (0.11 to 2.97) · 492 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.78 (0.16 to 1.41) · 3,923 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 50 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.428 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.535 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 63 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.5 · 339 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 42.6 · 181 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 31.7 · 92 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.6 · 180 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.5 to 7.6) · 155 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.5 (7.7 to 14.1) · 155 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 7.4 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.2 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 119 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.2 to 18.2) · 541 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 193 cases | No different | Jan 2024 – Dec 2024 |
What patients said (931 patients answered, 9% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 65% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Drugs they prescribed that Part D paid
$244,871
Pharmacies billed $244,871 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 792) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
571 generic and 221 brand-name prescriptions · $244,871 in drug cost · 25 antibiotic prescriptions to 21 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Veltassa | 68 | $59,933 | $881 |
| Velphoro | 17 | $43,661 | $2,568 |
| Jardiance | 34 | $36,884 | $1,085 |
| Lokelma | 32 | $21,470 | $671 |
| Sevelamer Carbonate | 62 | $14,001 | $226 |
See all 17 drugs
| Veltassa | 68 | $59,933 | $881 |
| Velphoro | 17 | $43,661 | $2,568 |
| Jardiance | 34 | $36,884 | $1,085 |
| Lokelma | 32 | $21,470 | $671 |
| Sevelamer Carbonate | 62 | $14,001 | $226 |
| Vascepa | 12 | $4,723 | $394 |
| Calcium Acetate | 25 | $3,735 | $149 |
| Amlodipine Besylate | 105 | $731 | $7 |
| Losartan | 47 | $320 | $7 |
| Furosemide | 30 | $270 | $9 |
| Hydralazine | 36 | $258 | $7 |
| Carvedilol | 23 | $208 | $9 |
| Famotidine | 12 | $150 | $12 |
| Omeprazole | 12 | $75 | $6 |
| Metoprolol | 11 | $49 | $4 |
| Lisinopril | 12 | $45 | $4 |
| Levofloxacin | 11 | $24 | $2 |
Year by year
| 2024 | 792 | 274 | 0% (0) | 28% | $244,871 |
| 2023 | 779 | 278 | 0% (0) | None | $281,288 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Renvela | 19 | $49,751 | $2,618 |
| Lokelma | 47 | $38,748 | $824 |
| Jardiance | 32 | $38,035 | $1,189 |
| Veltassa | 35 | $36,241 | $1,035 |
| Sevelamer Carbonate | 33 | $30,211 | $915 |
| Januvia | 12 | $9,600 | $800 |
| Calcium Acetate | 31 | $3,896 | $126 |
| Amlodipine Besylate | 94 | $1,195 | $13 |
| Losartan | 49 | $1,084 | $22 |
| Hydralazine | 48 | $711 | $15 |
| Carvedilol | 26 | $433 | $17 |
| Allopurinol | 17 | $379 | $22 |
| Gabapentin | 13 | $256 | $20 |
| Metoprolol | 13 | $240 | $18 |
| Furosemide | 33 | $192 | $6 |
| Metoprolol | 15 | $178 | $12 |
| Lisinopril | 12 | $133 | $11 |
| Levofloxacin | 18 | $97 | $5 |
| Glipizide | 12 | $65 | $5 |
Money from drug and device companies
$326 in 2025
| 2025 | 2 | 3 | None | $326 |
| 2024 | 1 | 1 | None | $120 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ardelyx | Ibsrela | $225 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $101 | 1 payment
|
See all 3 published payments
| Ardelyx | Meals · 2025-08-04 | Ibsrela | $101 |
| Ardelyx | Meals · 2025-07-29 | Ibsrela | $124 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-29 | Entyvio | $101 |
See earlier years (2024)
2024: $120
| Ardelyx | Ibsrela | $120 | 1 payment
|
Professional record
- NPI
- 1275249427
- Licence
- CA 95024077
- Group
- El Camino Health Medical Network LLC · The Board of Trustees of the University of Illinois
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 700 W Parr Ave Ste A, Los Gatos, CA, 95032
- NPI first listed
- 2023-01-30
- NPI last updated
- 2026-04-13
- NPI record certified
- 2026-04-13
This is when the NPI record was last certified, not a medical board exam.